is retatrutide on the market yet – new weight loss medication in development Retatrutide isn't supposed to be

You just said not to take some every day

[DOI] [PubMed] [Google Scholar] 56.Parikh S.K., Silberstein S.D

They An example of a short-acting GLP-1 RA approved for use in the United States is exenatide, which is injected subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 or more hours apart)

Tirzepatide does not prevent this metabolic adaptation entirely, but the degree of slowdown may be less than with diet-only weight loss

Weight Loss Injections AND Contraception or HRT Patient Warning: If you are using both a GLP-1 agonist (weight loss injection) and an oral contraception OR oral HRT the effectiveness of your contraception or HRT may be compromised